NextPlat Corp. (NASDAQ: NXPL, NXPLW) announced that its wholly owned pharmacy subsidiary, PharmcoRx, plans to introduce automated prescription dispensing kiosks from VendRx at select customer clinics and health care facilities. The kiosks will allow patients to obtain prescribed medications onsite following appointments and consultation with a PharmcoRx pharmacist, reducing the need for separate pharmacy visits. Initial installations are planned for the fourth quarter of 2026, with broader deployment expected throughout 2027.
The initiative is designed to improve medication access and adherence while expanding PharmcoRx’s prescription services and relationships with health care providers. VendRx reports approximately 80% formulary coverage per deployment and more than 90,000 successful prescription dispenses since inception, with no wrong-medication releases reported through Oct. 19, 2026, according to its internal records. NextPlat said the kiosks could help address gaps in pharmacy access, particularly in underserved communities, while allowing clinics to offer prescription dispensing without additional staffing or onsite pharmacy construction. The company expects the program to create an additional prescription channel for PharmcoRx and support its expansion through independent clinics and health care providers.
The move matters because it positions PharmcoRx to capture prescription volume at the point of care, where patients can receive medications immediately after consultations. For clinics, the kiosks offer a way to dispense prescriptions without hiring additional pharmacy staff or building an onsite pharmacy, potentially improving patient adherence and satisfaction. For NextPlat, the program represents a new channel for its pharmacy and healthcare data management services, which it operates through its subsidiary, Progressive Care. The company is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide.
Investors can view the full press release at https://ibn.fm/dIWEa and find the latest news and updates relating to NXPL in the company’s newsroom at https://ibn.fm/NXPL. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions. Full terms of use and disclaimers applicable to all content provided by BioMedWire are available at https://www.BioMedWire.com/Disclaimer.
